CRISPR for microbiome management, genetically

SNIPR Biome is at the forefront of developing CRISPR-based microbial gene therapy, focusing on precision killing of harmful bacteria while preserving beneficial microbiota. Their innovative approach utilizes CRISPR/Cas technology to create highly selective anti-bacterial drug candidates aimed at treating difficult conditions. By leveraging naturally derived technologies, such as bacteriophages for delivery and CRISPR/Cas for targeted killing, SNIPR Biome can effectively address specific bacterial species in the gut. This method allows for gut-directed gene therapy, where engineered live bacteria produce therapeutic molecules directly within the gastrointestinal tract, offering a novel alternative to traditional viral gene therapy.

The company's proprietary CRISPR technology enables rapid and precise destruction of targeted bacteria, with applications that include the treatment of multi-drug resistant infections, inflammatory bowel disease (IBD), and even cancer. Their CRISPR-Guided Vectors™ (CGV™ Technology) facilitate ultra-fast bacterial killing, achieving results in minutes. Additionally, SNIPR Biome's platform allows for the delivery of therapeutic genes to commensal bacteria, enabling the in situ production of proteins and peptides that can modulate the microbiome and address various health issues. This dual capability of selective bacterial killing and therapeutic gene delivery positions SNIPR Biome as a leader in the emerging field of microbiome-based therapies.

Denmark

SNIPR Biome is the leading CRISPR Microbiome company. Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future. Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota.

SNIPR BIOME

Company Details